U.S. mRNA Synthesis Raw Materials Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objection

1.2. Scope of the Study 

1.3. Definition 

Chapter 2. Research Methodology 

2.1. Research Approach 

2.2. Data Sources

2.3. Assumptions & Limitations 

Chapter 3. Executive Summary 

3.1. Market Snapshot 

Chapter 4. Market Variables and Scope  

4.1. Introduction 

4.2. Market Classification and Scope 

4.3. Industry Value Chain Analysis 

4.3.1. Raw Material Procurement Analysis  

4.3.2. Sales and Distribution Channel Analysis 

4.3.3. Downstream Buyer Analysis 

Chapter 5. COVID 19 Impact on U.S. mRNA Synthesis Raw Materials Market  

5.1. COVID-19 Landscape: U.S. mRNA Synthesis Raw Materials Industry Impact 

5.2. COVID 19 - Impact Assessment for the Industry 

5.3. COVID 19 Impact: Major Government Policy 

5.4. Market Trends and Opportunities in the COVID-19 Landscape 

Chapter 6. Market Dynamics Analysis and Trends 

6.1. Market Dynamics 

6.1.1. Market Drivers 

6.1.2. Market Restraints 

6.1.3. Market Opportunities 

6.2. Porter’s Five Forces Analysis 

6.2.1. Bargaining power of suppliers 

6.2.2. Bargaining power of buyers 

6.2.3. Threat of substitute 

6.2.4. Threat of new entrants 

6.2.5. Degree of competition 

Chapter 7. Competitive Landscape 

7.1.1. Company Market Share/Positioning Analysis 

7.1.2. Key Strategies Adopted by Players 

7.1.3. Vendor Landscape 

7.1.3.1. List of Suppliers 

7.1.3.2. List of Buyers 

Chapter 8. Global U.S. mRNA Synthesis Raw Materials Market, By Type 

8.1. U.S. mRNA Synthesis Raw Materials Market Revenue and Volume, by Type 

8.1.1 Nucleotides 

8.1.1.1. Market Revenue and Volume Forecast  

8.1.2. Capping Agents 

8.1.2.1. Market Revenue and Volume Forecast  

8.1.3. Enzymes 

8.1.3.1. Market Revenue and Volume Forecast  

8.1.4. Plasmid DNA 

8.1.4.1. Market Revenue and Volume Forecast  

8.1.5. Others 

8.1.5.1. Market Revenue and Volume Forecast  

Chapter 9. U.S. mRNA Synthesis Raw Materials Market, By Application 

9.1. U.S. mRNA Synthesis Raw Materials Market Revenue and Volume, by Application 

9.1.1. Vaccine Production 

9.1.1.1. Market Revenue and Volume Forecast  

9.1.2. Therapeutics Production 

9.1.2.1. Market Revenue and Volume Forecast  

9.1.3. Others   

9.1.3.1. Market Revenue and Volume Forecast   

Chapter 10. U.S. mRNA Synthesis Raw Materials Market, By End-Use 

10.1. U.S. mRNA Synthesis Raw Materials Market Revenue and Volume, by End-Use 

10.1.1. Biopharmaceutical & Pharmaceutical Companies 

10.1.1.1. Market Revenue and Volume Forecast  

10.1.2. CROs & CMOs 

10.1.2.1. Market Revenue and Volume Forecast  

10.1.3. Academic & Research Institutes   

10.1.3.1. Market Revenue and Volume Forecast  

Chapter 11. U.S. mRNA Synthesis Raw Materials Market, Estimates and Trend Forecast 

11.1. North America 

11.1.1. Market Revenue and Volume Forecast, by Type  

11.1.2. Market Revenue and Volume Forecast, by Application  

11.1.3. Market Revenue and Volume Forecast, by End-Use  

11.1.4. U.S. 

11.1.4.1. Market Revenue and Volume Forecast, by Type  

11.1.4.2. Market Revenue and Volume Forecast, by Application  

11.1.4.3. Market Revenue and Volume Forecast, by End-Use  

Chapter 12. Company Profiles 

12.1. Thermo Fisher Scientific Inc. 

12.1.1. Company Overview 

12.1.2. Product Offerings 

12.1.3. Financial Performance 

12.1.4. Recent Initiatives 

12.2. TriLink BioTechnologies 

12.2.1. Company Overview 

12.2.2. Product Offerings 

12.2.3. Financial Performance 

12.2.4. Recent Initiatives 

12.3. Aldevron 

12.3.1. Company Overview 

12.3.2. Product Offerings 

12.3.3. Financial Performance 

12.3.4. Recent Initiatives 

12.4. Merck KGaA 

12.4.1. Company Overview 

12.4.2. Product Offerings 

12.4.3. Financial Performance 

12.4.4. Recent Initiatives 

12.5. New England Biolabs 

12.5.1. Company Overview 

12.5.2. Product Offerings 

12.5.3. Financial Performance 

12.5.4. Recent Initiatives 

12.6. Moderna, Inc. 

12.6.1. Company Overview 

12.6.2. Product Offerings 

12.6.3. Financial Performance 

12.6.4. Recent Initiatives 

12.7. Pfizer Inc. 

12.7.1. Company Overview 

12.7.2. Product Offerings 

12.7.3. Financial Performance 

12.7.4. Recent Initiatives 

12.8. BOC Sciences 

12.8.1. Company Overview 

12.8.2. Product Offerings 

12.8.3. Financial Performance 

12.8.4. Recent Initiatives 

12.9. Creative Biogene 

12.9.1. Company Overview 

12.9.2. Product Offerings 

12.9.3. Financial Performance 

12.9.4. Recent Initiatives 

12.10. Evonik Industries AG 

12.10.1. Company Overview 

12.10.2. Product Offerings 

12.10.3. Financial Performance 

12.10.4. Recent Initiatives 

Chapter 13. Research Methodology 

13.1. Primary Research 

13.2. Secondary Research 

13.3. Assumptions 

Chapter 14. Appendix 

14.1. About Us 

14.2. Glossary of Terms